» Articles » PMID: 35325367

What Are Realistic Expectations to Become Free of Overactive Bladder Symptoms? Experience from Non-interventional Studies with Propiverine

Overview
Journal Adv Ther
Date 2022 Mar 24
PMID 35325367
Authors
Affiliations
Soon will be listed here.
Abstract

Introduction: Unmet expectations are a major cause of perceived treatment failure and discontinuation of treatment. To enable evidence-based counselling of patients on realistic expectations, we determined the chance of patients with overactive bladder becoming free of a given symptom upon treatment with a muscarinic antagonist in a non-interventional setting.

Methods: Two non-interventional studies included 1335 and 745 patients, respectively, who received 30 or 45 mg q.d. propiverine ER for 12 weeks. They were monitored for becoming free of urgency, urinary incontinence, frequency, or nocturia. Analyses were also performed in subgroups defined by basal symptom severity, age, and gender. Categorical data are shown as a percentage of the respective population. Continuous data are expressed as means or as median depending on whether the variability was considered to exhibit a normal distribution.

Results: The probability of becoming symptom-free was largest for incontinence and frequency (about 50%), but lesser for urgency (about 20%) and nocturia (about 10%). Greater basal severity of a symptom reduced the chance to become free of that symptom upon treatment, but the chance to become free of incontinence and frequency was still considerable. Age and gender had only minor if any effects on the chance of becoming symptom-free. These findings are in line with those of a limited number of randomized controlled trials.

Conclusion: These data provide an evidence base for the counselling of patients with overactive bladder on realistic expectations of treatment outcomes. We propose that realistic expectations can lead to greater long-term adherence.

Citing Articles

Dynamic phenotypic shifts and M2 receptor downregulation in bladder smooth muscle cells induced by mirabegron.

Muderrisoglu A, Ciotkowska A, Rutz B, Hu S, Qian S, Tamalunas A Front Pharmacol. 2024; 15:1446831.

PMID: 39114356 PMC: 11303193. DOI: 10.3389/fphar.2024.1446831.


Sex and Gender Differences in the Pharmacology of the Overactive Urinary Bladder.

Pautz A, Michel M Handb Exp Pharmacol. 2023; 282:57-74.

PMID: 37439844 DOI: 10.1007/164_2023_667.


Association of diabetes, hypertension, and their combination with basal symptoms and treatment responses in overactive bladder patients.

Muderrisoglu A, Sakul A, Murgas S, de la Rosette J, Michel M Front Pharmacol. 2023; 14:1144470.

PMID: 37063295 PMC: 10097919. DOI: 10.3389/fphar.2023.1144470.


Exploring Integrins in Smooth Muscle Function: Addressing Challenging Levels of Complexity and Deciphering Organ-specific Codes of Contraction?.

Hennenberg M Function (Oxf). 2022; 3(6):zqac053.

PMID: 36381383 PMC: 9646521. DOI: 10.1093/function/zqac053.

References
1.
Michel M, Goepel M . Treatment satisfaction of patients with lower urinary tract symptoms: randomised controlled trials vs. real life practice. Eur Urol. 2000; 38 Suppl 1:40-7. DOI: 10.1159/000052400. View

2.
Lucas M, Bosch R, Burkhard F, Cruz F, Madden T, Nambiar A . EAU guidelines on assessment and nonsurgical management of urinary incontinence. Eur Urol. 2012; 62(6):1130-42. DOI: 10.1016/j.eururo.2012.08.047. View

3.
Stav K, Dwyer P, Rosamilia A . Women overestimate daytime urinary frequency: the importance of the bladder diary. J Urol. 2009; 181(5):2176-80. DOI: 10.1016/j.juro.2009.01.042. View

4.
Cornu J, Abrams P, Chapple C, Dmochowski R, Lemack G, Michel M . A contemporary assessment of nocturia: definition, epidemiology, pathophysiology, and management--a systematic review and meta-analysis. Eur Urol. 2012; 62(5):877-90. DOI: 10.1016/j.eururo.2012.07.004. View

5.
Mazur D, Wehnert J, Dorschner W, Schubert G, Herfurth G, Alken R . Clinical and urodynamic effects of propiverine in patients suffering from urgency and urge incontinence. A multicentre dose-optimizing study. Scand J Urol Nephrol. 1995; 29(3):289-94. DOI: 10.3109/00365599509180578. View